- Focal therapy for prostate cancer with irreversible electroporation: Oncological and functional results of a single institution study
-
Yaxley WJ, Gianduzzo T, Kua B, Oxford R, Yaxley JW
- KMID: 2530918
- Investig Clin Urol.
- 2022 Jul;63(4):482-482.
- doi: 10.4111/icu.20210472c
-
- CITED
-
- Close
- SHARE
-
- Close
- Focal therapy for prostate cancer with irreversible electroporation: Oncological and functional results of a single institution study
-
Yaxley WJ, Gianduzzo T, Kua B, Oxford R, Yaxley JW
- KMID: 2529347
- Investig Clin Urol.
- 2022 May;63(3):285-293.
- doi: 10.4111/icu.20210472
Purpose: Focal irreversible electroporation (IRE) for prostate cancer aims to reduce quality of life complications, however outcomes data remains limited. We aimed to evaluate histological in-field clearance of prostate cancer... -
- CITED
-
- Close
- SHARE
-
- Close
- Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?
-
Yaxley WJ, McBean R, David W, David G, Paul V, Mark F, Yaxley JW
- KMID: 2521818
- Investig Clin Urol.
- 2021 Nov;62(6):650-657.
- doi: 10.4111/icu.20210097
Purpose: Lutetium labelled prostate-specific membrane antigen radioligand therapy (Lu-PSMA RLT) has shown pleasing early results in management of high-volume metastatic castration resistant prostate cancer (mCRPC), but its role in the... -
- CITED
-
- Close
- SHARE
-
- Close
